TABLE 1.

Baseline characteristics of 13,431 HIV-infected participants stratified by co-trimoxazole use

Characteristica	Total	Result for participants:		P value
		Never treated with co-trimoxazole	Ever treated with co-trimoxazole
Participants, no. (%)	13,431 (100)	8,166 (61)	5,265 (39)
Yr of baseline visit, median (IQR)	1998 (1993–2005)	2000 (1995–2006)	1996 (1992–2001)	<0.001
Female, no. (%)	3,815 (100)	2,293 (60)	1,522 (40)	0.299
Age, median yr (IQR)	35 (30–42)	34 (29–41)	35 (30–43)	<0.001
Nadir CD4, median cells/μl (IQR)	273 (129–448)	355 (228–525)	150 (61–274)	<0.001
Nadir CD4 of <200 cells/μl, no. (%)	4,602 (100)	1,510 (33)	3,092 (67)	<0.001
Risk groups and respective % with nadir CD4 of <200/cells μl, no. (%)
Heterosexuals	4,521 (100)	2,292 (60)	1,829 (40)	<0.001
Nadir CD4 of <200 cells/μl	1,697 (100)	510 (30)	1187 (70)	<0.001
IDU	3,108 (100)	1,591 (51)	1,517 (49)
Nadir CD4 of <200 cells/μl	1,084 (100)	349 (32)	735 (68)	<0.001
MSM	5,271 (100)	3,583 (68)	1,688 (32)
Nadir CD4 of <200 cells/μl	1,618 (100)	597 (37)	1021 (63)	<0.001
Other	531 (100)	300 (57)	231 (44)
Nadir CD4 of <200 cells/μl	203 (100)	54 (27)	149 (73)	<0.001
Ethnicity, no. (%)
Caucasianb	11,074 (100)	6,679 (60)	4,395 (40)	0.012
Other	2,357 (100)	1,487 (64)	870 (37)
CDC stage, no. (%)
A	8,497 (100)	6,111 (72)	2,386 (29)	<0.001
B	2,237 (100)	1,131 (51)	1,106 (49)
C	2,697 (100)	924 (34)	1,773 (66)
Nadir CD4, median cells/μl (IQR)	273 (129–448)	355 (228–525)	150 (61–274)	<0.001
TST at enrollment, no. (%)
Test performed	8,989 (100)	5,088 (62)	3901 (74)	<0.001
TST positive	365 (100)	270 (5)	95 (2)	<0.001

^aAbbrevations: IDU, intravenous drug use; MSM, men who have sex with men; TST, tuberculin skin test.

^bSHCS participants from northwestern Europe, North America, and Australia.